Effect of neoadjuvant chemotherapy on distraction osteogenesis in the goat model.
Neoadjuvant chemotherapy potentially can have an adverse effect on bone healing in distraction osteogenesis whether given before or concomitant with distraction osteogenesis. It was the purpose of the current study to determine if administration of chemotherapy before distraction adversely affects bone generation in distraction osteogenesis. Twenty-four adult dairy goats were divided randomly into two groups: a control group having distraction osteogenesis only and a chemotherapy group, receiving one course of Adriamycin before distraction osteogenesis. The animals were sacrificed at 6 weeks, 12 weeks, or 24 weeks and the lengthened tibias were evaluated by radiologic studies, biomechanical testing, and histologic analysis. All goats receiving chemotherapy showed systemic adverse effects. In a multifactorial analysis of the lengthened bones, there was no statistically significant difference between the control goats versus goats that received chemotherapy; indicating that there was no sustained inhibitory effect on bone formation by the chemotherapy. These findings suggest that a prior course of chemotherapy with Adriamycin may not be a contraindication to limb lengthening for limb salvage after resection of an osteosarcoma.
Gravel
Charles A
CA
Orthopaedic Research Laboratories, University of California, Davis, Sacramento, USA.
Le
T Toan
TT
Chapman
Michael W
MW
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D001696:Biomechanical Phenomena; D015519:Bone Density / Q000187:drug effects; D017024:Chemotherapy, Adjuvant; D004317:Doxorubicin / Q000494:pharmacology*; D006041:Goats; D023421:Models, Animal; D010012:Osteogenesis / Q000187:drug effects*; D019857:Osteogenesis, Distraction / Q000379:methods*; D011859:Radiography; D013977:Tibia / Q000000981:diagnostic imaging / Q000473:pathology / Q000601:surgery; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D004317:Doxorubicin